Artivion delivered an exceptionally strong second quarter in 2025, achieving $113.0 million in revenue, a 15% increase year-over-year. The company reported a net income of $1.3 million and a non-GAAP net income of $10.7 million. Adjusted EBITDA saw a substantial 33% increase to $24.8 million, demonstrating the company's ability to scale and expand margins. Key drivers for revenue growth included On-X and stent grafts, both growing over 20% on a constant currency basis.
Total revenue for Q2 2025 reached $113.0 million, marking a 15% increase from Q2 2024.
Net income for the quarter was $1.3 million, with non-GAAP net income at $10.7 million.
Adjusted EBITDA significantly increased by 33% to $24.8 million in Q2 2025.
The company received IDE approval for the ARTIZEN pivotal trial and successfully retired $99.5 million in convertible senior notes, improving its capital structure.
Artivion is raising the midpoint of its full-year 2025 constant currency revenue and adjusted EBITDA guidance, reflecting strong Q2 performance and continued business momentum.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance